Search

Search Constraints

You searched for: Author/Creator Mey, Ulrich J. M.

Search Results

1. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd‐line therapy for relapsed and refractory multiple myeloma – a phase II trial. (16th December 2016)